Found the Spark Plus video from March 2021. @samfiodiving @George1972 @waynesworld
This is GOLD - Mark's best ever performance.
Let me quote Mark at 43:18
"You can see the quote from one of our DMD experts based in the UK, Prof Thomas Voit - He's going to be our PI in the Phase IIB clinical trial......"
We were not hearing things - Mark definitely said Prof Voit was going to be PI for EMA trial.
Prof Voit was very excited about ATL1102 results when interviewed by Shane Story from Wilsons.
Prof Voit is also part owner of the patent Sarepta are using for "micro-dystrophin".
Join the dots and we get: Combination Therapy....firstly with Exondys51 then with Gene Therapy.
47:07 - Mark makes reference to Sarepta's GT failure.
51:40 - Mark throws shade at Sarepta's efficacy
49:10 - New indications.
20210326 - Spark Plus Q1 BioTech Day - YouTube
Found the Spark Plus video from March 2021. @samfiodiving...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.001(1.35%) |
Mkt cap ! $68.51M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.6¢ | 7.4¢ | $12.76K | 168.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36234 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 143169 | 1 |
View Market Depth
| Last trade - 11.18am 24/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.001 ( 1.33 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.6¢ | 7.6¢ | 1717 | ||
| Last updated 10.26am 24/04/2024 ? | |||||
| PER (ASX) Chart |